BACKGROUND: Previous studies reported that prostate cancer incidence rates in the United States declined for local-stage disease and increased for regional- and distant-stage disease following the US Preventive Services Task Force recommendations against prostate-specific antigen-based screening for men aged 75 years and older in 2008 and for all men in 2012. It is unknown, however, whether these patterns persisted through 2016. METHODS: Based on the US Cancer Statistics Public Use Research Database, we examined temporal trends in invasive prostate cancer incidence from 2005 to 2016 in men aged 50 years and older stratified by stage (local, regional, and distant), age group (50-74 years and 75 years and older), and race and ethnicity (all races and ethnicities, non-Hispanic Whites, and non-Hispanic Blacks) with joinpoint regression models to estimate annual percent changes. Tests of statistical significance are 2-sided (P < .05). RESULTS: For all races and ethnicities combined, incidence for local-stage disease declined beginning in 2007 in men aged 50-74 years and 75 years and older, although the decline stabilized during 2013-2016 in men aged 75 years and older. Incidence decreased by 6.4% (95% CI = 4.9%-9% to 7.9%) per year from 2007 to 2016 in men aged 50-74 years and by 10.7% (95% CI = 6.2% to 15.0%) per year from 2007 to 2013 in men aged 75 years and older. In contrast, incidence for regional- and distant-stage disease increased in both age groups during the study period. For example, distant-stage incidence in men aged 75 years and older increased by 5.2% (95% CI = 4.2% to 6.1%) per year from 2010 to 2016. CONCLUSIONS: Regional- and distant-stage prostate cancer incidence continue to increase in the United States in men aged 50 years and older, and future studies are needed to identify reasons for the rising trends.
BACKGROUND: Previous studies reported that prostate cancer incidence rates in the United States declined for local-stage disease and increased for regional- and distant-stage disease following the US Preventive Services Task Force recommendations against prostate-specific antigen-based screening for men aged 75 years and older in 2008 and for all men in 2012. It is unknown, however, whether these patterns persisted through 2016. METHODS: Based on the US Cancer Statistics Public Use Research Database, we examined temporal trends in invasive prostate cancer incidence from 2005 to 2016 in men aged 50 years and older stratified by stage (local, regional, and distant), age group (50-74 years and 75 years and older), and race and ethnicity (all races and ethnicities, non-Hispanic Whites, and non-Hispanic Blacks) with joinpoint regression models to estimate annual percent changes. Tests of statistical significance are 2-sided (P < .05). RESULTS: For all races and ethnicities combined, incidence for local-stage disease declined beginning in 2007 in men aged 50-74 years and 75 years and older, although the decline stabilized during 2013-2016 in men aged 75 years and older. Incidence decreased by 6.4% (95% CI = 4.9%-9% to 7.9%) per year from 2007 to 2016 in men aged 50-74 years and by 10.7% (95% CI = 6.2% to 15.0%) per year from 2007 to 2013 in men aged 75 years and older. In contrast, incidence for regional- and distant-stage disease increased in both age groups during the study period. For example, distant-stage incidence in men aged 75 years and older increased by 5.2% (95% CI = 4.2% to 6.1%) per year from 2010 to 2016. CONCLUSIONS: Regional- and distant-stage prostate cancer incidence continue to increase in the United States in men aged 50 years and older, and future studies are needed to identify reasons for the rising trends.
Authors: Roman Gulati; Alex Tsodikov; Ruth Etzioni; Rachel A Hunter-Merrill; John L Gore; Angela B Mariotto; Matthew R Cooperberg Journal: Cancer Date: 2014-07-25 Impact factor: 6.860
Authors: Jim C Hu; Paul Nguyen; Jialin Mao; Joshua Halpern; Jonathan Shoag; Jason D Wright; Art Sedrakyan Journal: JAMA Oncol Date: 2017-05-01 Impact factor: 31.777
Authors: Roman Gulati; Heather H Cheng; Paul H Lange; Peter S Nelson; Ruth Etzioni Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10-14 Impact factor: 4.254
Authors: Adrien N Bernstein; Jonathan E Shoag; Ron Golan; Joshua A Halpern; Edward M Schaeffer; Wei-Chun Hsu; Paul L Nguyen; Art Sedrakyan; Ronald C Chen; Scott E Eggener; Jim C Hu Journal: J Urol Date: 2017-12-26 Impact factor: 7.450
Authors: Stacey A Fedewa; Ted Gansler; Robert Smith; Ann Goding Sauer; Richard Wender; Otis W Brawley; Ahmedin Jemal Journal: Ann Fam Med Date: 2018-03 Impact factor: 5.166
Authors: Alex Tsodikov; Roman Gulati; Tiago M de Carvalho; Eveline A M Heijnsdijk; Rachel A Hunter-Merrill; Angela B Mariotto; Harry J de Koning; Ruth Etzioni Journal: Cancer Date: 2017-04-24 Impact factor: 6.860
Authors: Ying Han; Kristin A Rand; Dennis J Hazelett; Sue A Ingles; Rick A Kittles; Sara S Strom; Benjamin A Rybicki; Barbara Nemesure; William B Isaacs; Janet L Stanford; Wei Zheng; Fredrick R Schumacher; Sonja I Berndt; Zhaoming Wang; Jianfeng Xu; Nadin Rohland; David Reich; Arti Tandon; Bogdan Pasaniuc; Alex Allen; Dominique Quinque; Swapan Mallick; Dimple Notani; Michael G Rosenfeld; Ranveer Singh Jayani; Suzanne Kolb; Susan M Gapstur; Victoria L Stevens; Curtis A Pettaway; Edward D Yeboah; Yao Tettey; Richard B Biritwum; Andrew A Adjei; Evelyn Tay; Ann Truelove; Shelley Niwa; Anand P Chokkalingam; Esther M John; Adam B Murphy; Lisa B Signorello; John Carpten; M Cristina Leske; Suh-Yuh Wu; Anslem J M Hennis; Christine Neslund-Dudas; Ann W Hsing; Lisa Chu; Phyllis J Goodman; Eric A Klein; S Lilly Zheng; John S Witte; Graham Casey; Alex Lubwama; Loreall C Pooler; Xin Sheng; Gerhard A Coetzee; Michael B Cook; Stephen J Chanock; Daniel O Stram; Stephen Watya; William J Blot; David V Conti; Brian E Henderson; Christopher A Haiman Journal: J Natl Cancer Inst Date: 2016-01-27 Impact factor: 13.506
Authors: Serban Negoita; Eric J Feuer; Angela Mariotto; Kathleen A Cronin; Valentina I Petkov; Sarah K Hussey; Vicki Benard; S Jane Henley; Robert N Anderson; Stacey Fedewa; Recinda L Sherman; Betsy A Kohler; Barbara J Dearmon; Andrew J Lake; Jiemin Ma; Lisa C Richardson; Ahmedin Jemal; Lynne Penberthy Journal: Cancer Date: 2018-05-22 Impact factor: 6.860
Authors: Qing Kay Li; Tung-Shing Mamie Lih; Yuefan Wang; Yingwei Hu; Naseruddin Höti; Daniel W Chan; Hui Zhang Journal: Am J Cancer Res Date: 2022-03-15 Impact factor: 6.166
Authors: Leonardo D Borregales; Gina DeMeo; Xiangmei Gu; Emily Cheng; Vanessa Dudley; Edward M Schaeffer; Himanshu Nagar; Sigrid Carlsson; Andrew Vickers; Jim C Hu Journal: J Natl Cancer Inst Date: 2022-07-11 Impact factor: 11.816
Authors: Amir Goldkorn; Catherine Tangen; Melissa Plets; Gareth J Morrison; Alexander Cunha; Tong Xu; Jacek K Pinski; Sue A Ingles; Timothy Triche; Andrea L Harzstark; Manish Kohli; Gary R MacVicar; Daniel A Vaena; Anthony W Crispino; David J McConkey; Primo N Lara; Maha H A Hussain; David I Quinn; Nicholas J Vogelzang; Ian Murchie Thompson; Neeraj Agarwal Journal: Clin Cancer Res Date: 2021-01-26 Impact factor: 13.801
Authors: Kevin H Kensler; Claire H Pernar; Brandon A Mahal; Paul L Nguyen; Quoc-Dien Trinh; Adam S Kibel; Timothy R Rebbeck Journal: J Natl Cancer Inst Date: 2021-06-01 Impact factor: 13.506
Authors: Rutvij A Khanolkar; Harvey Quon; Kundan Thind; Michael Sia; Michael Roumeliotis; Siraj Husain; Philip McGeachy; Tyler Meyer; Kevin Martell Journal: Clin Transl Radiat Oncol Date: 2021-07-01